• Omeros Corporation reported past first-quarter 2026 results showing sales of US$9.89 million and a shift from a net loss to net income of US$56.06 million, with both basic and diluted earnings per share turning positive versus the prior year.
• Beyond the headline profit swing, the quarter reflects earnings power influenced by noncash items and comes alongside ongoing regulatory and clinical momentum for YARTEMLEA and the broader complement pipeline.
• We’ll now examine how this sharp earnings turnaround, driven in part by noncash factors, affects Omeros’ earlier investment narrative and assumptions.

This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

Omeros Investment Narrative Recap

To own Omeros, you need to believe its complement platform, anchored by YARTEMLEA in TA TMA, can translate into durable, commercially relevant therapies. The sharp Q1 2026 profit swing, aided by noncash items, does not materially change the key near term catalyst, which remains the early U.S. launch trajectory of YARTEMLEA, nor the biggest risk, which is regulatory and commercial execution around that product and its label.

The Q1 2026 earnings release is most relevant here because it highlights how mark to market and other noncash adjustments can move reported net income far more than the underlying US$9.89 million in sales. For investors tracking YARTEMLEA’s rollout and Omeros’ liquidity, this reinforces the need to separate accounting volatility from the core question of how quickly the new therapy converts into recurring product revenue.

Yet investors should be aware that behind the headline profitability, continued swings from noncash accounting items could still...

Omeros' narrative projects $387.3 million in revenue and $135.4 million in earnings by 2029. This implies an earnings increase of about $256.6 million from -$121.2 million today.

Uncover how Omeros' forecasts yield a $38.00 fair value, a 164% upside to its current price.

Exploring Other Perspectives

Four fair value estimates from the Simply Wall St Community span from US$1.50 to US$248.22 per share, underlining how far apart individual views can be. Against that backdrop, the recent profit uplift partly driven by noncash items may prompt you to weigh how much of Omeros’ apparent earnings power reflects accounting effects rather than the underlying trajectory of its complement franchise.

Explore 4 other fair value estimates on Omeros - why the stock might be worth less than half the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Omeros research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Omeros research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Omeros' overall financial health at a glance.

Searching For A Fresh Perspective?

Our top stock finds are flying under the radar-for now. Get in early:

• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.